A new treatment for ocular neovascularization

New England Journal of Medicine

Volumn 351, Issue 27, 2004, Pages 2863-2865

  Ferris III, Frederick L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

BLINDNESS; DISEASE ASSOCIATION; EDITORIAL; FOLLOW UP; HUMAN; LASER COAGULATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA NEOVASCULARIZATION; RISK ASSESSMENT; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

CHOROIDAL NEOVASCULARIZATION; HUMANS; INJECTIONS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11144230020     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048316     Document Type: Editorial

References (12)

1. Ferris FL III, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999;341:667-78.
2. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
3. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 1986;104:34-41.
4. Ferris FL III. How effective are treatments for diabetic retinopathy? Commentary. JAMA 1993;269:1290-1.
5. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
6. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol 1986;104:694-701.
7. Idem. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-14. [Erratum, Arch Ophthalmol 1992;110:761.]
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-45. [Erratum, Arch Ophthalmol 2000;118:488.]
9. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-18.
10. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K 1948;68:137-90.
11. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.